Personalis Shares Rise After Medicare Grants Coverage for Lung Cancer MRD Test
Personalis Inc. saw a notable one-day stock gain after Medicare approved coverage for its NeXT Personal molecular residual disease (MRD) test for surveillance of Stage I to III non-small cell lung cancer. The decision, grounded in clinical data from a collaboration with the TRACERx consortium, follows a separate coverage determination for breast ca…